Publications by authors named "Virginia Taliadouros"
Article Synopsis
- Filgotinib, an oral medication for ulcerative colitis, has shown promising results in long-term treatment outcomes based on findings from the SELECTION trial.
- Researchers used group-based trajectory modeling to classify patients’ symptom responses over time, identifying five distinct patient groups based on their treatment responses.
- A majority of patients showed positive response trajectories, with factors such as recent diagnosis, usage of a higher filgotinib dose, and being biologic-naive linked to better outcomes and greater chances of achieving comprehensive disease control.
Background And Aims: The efficacy of new therapies for ulcerative colitis [UC] is usually influenced by previous biologic use. These post hoc analyses of SELECTION, a placebo-controlled phase 2b/3 trial in patients with moderately to severely active UC, evaluated the efficacy of filgotinib, an oral Janus 1 kinase preferential inhibitor, with respect to prior biologic failure.
Methods: The effect of filgotinib 200 mg (FIL200) relative to placebo was compared in biologic-naïve and biologic-failed patient groups, and in further subgroups by number of failed biologics [1 or >1], biologic mechanism of action [MoA] classes [1 or 2] and tumour necrosis factor [TNF] antagonists [1 or >1].
To understand relationships between phosphorylation-based signaling pathways, we analyzed 150 deletion mutants of protein kinases and phosphatases in S. cerevisiae using DNA microarrays. Downstream changes in gene expression were treated as a phenotypic readout.
View Article and Find Full Text PDFQuality of life and employment status of workers with Western red cedar asthma.
J Occup Environ Med
September 2007
Objective: The impact of current employment status and other factors on quality of life was evaluated for workers diagnosed with western red cedar asthma in British Columbia, Canada.
Methods: Telephone interviews by questionnaire included the Short Form 36 (SF-36) and Marks Asthma quality-of-life instruments.
Results: Of the 302 subjects contacted, 70.